Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis.

Jandhyala R, Fullarton J.

BMJ Support Palliat Care. 2012 Jun;2(2):156-62. doi: 10.1136/bmjspcare-2011-000139. Review.

PMID:
24654058
2.

Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.

Jandhyala R, Fullarton JR, Bennett MI.

J Pain Symptom Manage. 2013 Oct;46(4):573-80. doi: 10.1016/j.jpainsymman.2012.09.009. Review.

3.

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, McCracken M, Portenoy RK.

Pain. 2001 Mar;91(1-2):123-30.

PMID:
11240084
4.

Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer.

Vissers D, Stam W, Nolte T, Lenre M, Jansen J.

Curr Med Res Opin. 2010 May;26(5):1037-45. doi: 10.1185/03007991003694340.

PMID:
20199140
5.

Opioids for the management of breakthrough pain in cancer patients.

Zeppetella G, Davies AN.

Cochrane Database Syst Rev. 2013 Oct 21;(10):CD004311. doi: 10.1002/14651858.CD004311.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(8):CD004311.

PMID:
24142465
6.

Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.

Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick R, Howell J.

Curr Med Res Opin. 2009 Dec;25(12):2877-85. doi: 10.1185/03007990903368310.

PMID:
19814586
7.

Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.

Mercadante S, Ferrera P, Adile C, Casuccio A.

J Pain Symptom Manage. 2011 Sep;42(3):464-9. doi: 10.1016/j.jpainsymman.2010.12.010.

PMID:
21477977
8.

Fentanyl buccal tablet.

Messina J, Darwish M, Fine PG.

Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. Review.

PMID:
18301803
10.

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.

Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA.

Curr Med Res Opin. 2009 Nov;25(11):2805-15. doi: 10.1185/03007990903336135.

PMID:
19792837
11.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M.

Pain. 1999 Feb;79(2-3):303-12.

PMID:
10068176
12.

Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.

Elsner F, Zeppetella G, Porta-Sales J, Tagarro I.

Clin Drug Investig. 2011;31(9):605-18. doi: 10.2165/11592910-000000000-00000. Review.

PMID:
21819159
13.

Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.

Guitart J, Vargas I, De Sanctis V, Ferreras J, Fuentes J, Salazar R, Vázquez JM, Folch J, Moya J, Ribera H, Rodelas F, Tomás A, Arilla M, Coma J, Aberasturi T, Sintes D, Lombán E.

Clin Drug Investig. 2013 Sep;33(9):675-83. doi: 10.1007/s40261-013-0111-z.

PMID:
23881567
14.

A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.

Zeppetella G, Davies A, Eijgelshoven I, Jansen JP.

J Pain Symptom Manage. 2014 Apr;47(4):772-785.e5. doi: 10.1016/j.jpainsymman.2013.05.020. Review.

PMID:
23981487
15.

Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.

Velázquez Rivera I, Muñoz Garrido JC, García Velasco P, España Ximénez de Enciso I, Velázquez Clavarana L.

Adv Ther. 2014 Jan;31(1):107-17. doi: 10.1007/s12325-013-0086-4.

PMID:
24385406
16.

Evidence-based treatment of cancer-related breakthrough pain with opioids.

Zeppetella G.

J Natl Compr Canc Netw. 2013 Mar;11 Suppl 1:S37-43.

PMID:
23520185
17.

A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.

Novotna S, Valentova K, Fricova J, Richterova E, Harabisova S, Bullier F, Trinquet F; ETHYFYL Study Group..

Clin Ther. 2014 Mar 1;36(3):357-67. doi: 10.1016/j.clinthera.2014.01.006.

PMID:
24508417
18.

Opioids for the management of breakthrough (episodic) pain in cancer patients.

Zeppetella G, Ribeiro MD.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004311. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD004311.

PMID:
16437482
19.

The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain.

Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B.

Anesth Analg. 1999 Sep;89(3):732-8.

PMID:
10475315
20.

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.

Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E.

J Natl Cancer Inst. 1998 Apr 15;90(8):611-6.

PMID:
9554444

Supplemental Content

Support Center